Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis
Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final ...
Healio5h
Winrevair PAH trial stopped due to earlier ‘robust evidence’
The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two or three is ending early due to robust positive evidence found in previous ...
appliedclinicaltrialsonline4d
Merck Stops HYPERION Trial for Winrevair in PAH Following Positive ZENITH Trial Results
The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the efficacy of Winrevair (sotatercept-csrk) in treating pulmonary arterial ...
Managed Healthcare Executive4d
Another Trial of Winrevair Stopped Early Due to Positive Efficacy
The HYPERION study was evaluating Winrevair in recently diagnosed adults with pulmonary arterial hypertension.
Zacks.com on MSN3d
Merck Halts Second PAH Drug Study Early on Strong Efficacy Results
MRK's decision to stop the late-stage HYPERION study on PAH drug Winrevair ahead of time comes after evaluating the drug's ...
PharmiWeb3d
Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis
WINREVAIR is currently approved in the U.S. and 38 countries based on the results from the Phase 3 STELLAR trial. *World Health Organization **Dr. McLaughlin is a member of the adult sotatercept ...
Morningstar4d
Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis
WINREVAIR is currently approved in the U.S. and 38 countries based on the results from the Phase 3 STELLAR trial. *World Health Organization **Dr. McLaughlin is a member of the adult sotatercept ...
Le Lézard4d
Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIRtm (sotatercept-csrk) Early and Move to Final Analysis
Merck , known as MSD outside of the United States and Canada, announced today the Phase 3 HYPERION study evaluating WINREVAIR (sotatercept-csrk) versus placebo (both in combination with background ...
Daily3d
Merck to stop trial evaluating Winrevair early in pulmonary arterial hypertension
Rahway: Merck, known as MSD outside of the United States and Canada, has announced the Phase 3 HYPERION study evaluating ...
The Pharma Letter4d
Merck halts Winrevair HYPERION trial early on positive results
US pharma giant Merck & Co today revealed an early stop to the Phase III HYPERION study evaluating Winrevair (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently ...